Certolizumab Inhibits Radiographic Progression Even in RA Patients with High Rheumatoid Factor Levels: A Pooled, Post-Hoc Analysis of Two Phase 3 Trials

被引：0
|
作者：
Smolen, Josef [1 ]
Burmester, Gerd [2 ]
Tanaka, Yoshiya [3 ]
Takeuchi, Tsutomu [4 ]
Curtis, Jeffrey [5 ]
Mikuls, Ted [6 ]
Lopez Medina, Clementina [7 ]
Taylor, Peter C. [8 ]
Tilt, Nicola [9 ]
Lauwerys, Bernard [10 ]
Ufuktepe, Baran [11 ]
Huizinga, Thomas [12 ]
机构：
[1] Med Univ Vienna, Vienna, Austria
[2] Charite Univ Med Berlin, Dept Rheumatol & Clin Immunol, Berlin, Germany
[3] Univ Occupat & Environm Hlth, Dept Internal Med, Kitakyushu, Fukuoka, Japan
[4] Keio Univ, Dept Internal Med, Tokyo, Japan
[5] Univ Alabama Birmingham, Birmingham, AL USA
[6] Univ Nebraska Med Ctr, Omaha, NE USA
[7] Reina Sofia Univ Hosp, Cordoba, Spain
[8] Univ Oxford, Oxford, England
[9] UCB Pharma, Slough, England
[10] UCB Pharma, Brussels, Belgium
[11] UCB Pharma, Istanbul, Turkiye
[12] Leiden Univ, Dept Rheumatol, Leiden, Netherlands
来源：
ARTHRITIS & RHEUMATOLOGY | 2024年 / 76卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2286
引用
收藏
页码：4597 / 4600
页数：4
相关论文
共 50 条
  • [21] EFFICACY OF TOFACITINIB BY BACKGROUND METHOTREXATE DOSE IN PATIENTS WITH PSORIATIC ARTHRITIS: A POST-HOC ANALYSIS OF POOLED DATA FROM 2 PHASE 3 TRIALS
    Kivitz, A. J.
    FitzGerald, O.
    Nash, P.
    Pang, S.
    Azevedo, V. F.
    Kudlacz, E.
    Wang, C.
    Graham, D.
    Takiya, L.
    ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 1575 - 1575
  • [22] Benefit of Filgotinib, a JAK1 Preferential Inhibitor, in Rheumatoid Arthritis Patients with Previous Rapid Radiographic Progression: Post Hoc Analysis of Two Trials
    Tanaka, Yoshiya
    Atsumi, Tatsuya
    Aletaha, Daniel
    Bartok, Beatrix
    Pechonkina, Alena
    Han, Ling
    Emoto, Kahaku
    Kano, Shungo
    Rajendran, Vijay
    Takeuchi, Tsutomu
    RHEUMATOLOGY AND THERAPY, 2023, 10 (01) : 161 - 185
  • [23] Benefit of Filgotinib, a JAK1 Preferential Inhibitor, in Rheumatoid Arthritis Patients with Previous Rapid Radiographic Progression: Post Hoc Analysis of Two Trials
    Yoshiya Tanaka
    Tatsuya Atsumi
    Daniel Aletaha
    Beatrix Bartok
    Alena Pechonkina
    Ling Han
    Kahaku Emoto
    Shungo Kano
    Vijay Rajendran
    Tsutomu Takeuchi
    Rheumatology and Therapy, 2023, 10 : 161 - 185
  • [24] EFFICACY OF MIRABEGRON IN OVERACTIVE BLADDER PATIENTS STRATIFIED BY SEVERITY OF BASELINE INCONTINENCE: A POST-HOC ANALYSIS OF POOLED DATA FROM 3 RANDOMISED PHASE 3 TRIALS
    Chapple, C. R.
    Khullar, V.
    Nitti, V. W.
    Herschorn, S.
    Kaper, M.
    Dorrepaal, C.
    Martin, N.
    Siddiqui, E.
    INTERNATIONAL UROGYNECOLOGY JOURNAL, 2013, 24 : S12 - S13
  • [25] CONFOUNDING EFFECTS OF CONTINUED METHOTREXATE IN PLACEBO ARMS (PLC) OF RHEUMATOID ARTHRITIS (RA) CLINICAL TRIALS - A POST-HOC ANALYSIS OF TWO RANDOMIZED CONTROLLED TRIALS (RCTS)
    Kerschbaumer, A.
    Rivai, Z. I.
    Smolen, J. S.
    Aletaha, D.
    ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 71 - 72
  • [26] C-Reactive Protein Levels in Patients with or without Structural Progression: A Post-Hoc Analysis from a Phase 3 Tofacitinib Trial
    Fleischmann, Roy
    Connell, Carol A.
    Fan, Haiyun
    Strengholt, Sander
    ARTHRITIS & RHEUMATOLOGY, 2017, 69
  • [27] Effect of daridorexant on sleep micro-architecture in adult patients with insomnia disorder: A post-hoc analysis of two pooled Phase 3 studies
    Di Marco, Tobias
    Djonlagic, Ina
    Dauvilliers, Yves
    Tjiptarto, Nurkurniati
    Arslan, Alex
    Datta, Alexandre
    Hajak, Goeran
    Hubbard, Jeffrey
    Kleinschmidt, Dave
    Krystal, Andrew
    Little, David
    Olivieri, Antonio
    Parrino, Liborio
    Pathmanathan, Jay
    Sadeghi, Kolia
    Westover, Brandon
    Zammit, Gary
    Donoghue, Jacob
    Scammell, Thomas
    JOURNAL OF SLEEP RESEARCH, 2024, 33
  • [28] DO HIGH RHEUMATOID FACTOR TITRES IMPACT RESPONSE TO TUMOUR NECROSIS FACTOR INHIBITORS? COMPARISON OF CERTOLIZUMAB PEGOL AND ADALIMUMAB IN PATIENTS WITH RHEUMATOID ARTHRITIS AND HIGH TITRES OF RHEUMATOID FACTOR: A POST HOC ANALYSIS OF A PHASE 4 TRIAL
    Smolen, Josef S.
    Taylor, Peter C.
    Tanaka, Yoshiya
    Cara, Carlos
    Lauwerys, Bernard
    Xavier, Ricardo
    Curtis, Jeffrey R.
    Mikuls, Ted R.
    Weinblatt, Michael
    RHEUMATOLOGY, 2024, 63
  • [29] RADIOGRAPHIC PROGRESSION IN MODERN RA TRIALS IS STILL A ROBUST OUTCOME: RESULTS OF COMPREHENSIVE SENSITIVITY ANALYSIS IN TWO PHASE 3 TRIALS WITH TOFACITINIB
    van der Heijde, D.
    Connell, C.
    Bradley, J.
    Gruben, D.
    Strengholt, S.
    Landewe, R. B.
    ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 : 737 - 737
  • [30] Do high rheumatoid factor titres impact response to tumour necrosis factor inhibitors? Comparison of certolizumab pegol and adalimumab in patients with rheumatoid arthritis and high titres of rheumatoid factor: a post hoc analysis of a phase 4 trial.
    Smolen, Josef S.
    Taylor, Peter C.
    Tanaka, Yoshiya
    Cara, Carlos
    Lauwerys, Bernard
    Xavier, Ricardo
    Curtis, Jeffrey R.
    Mikuls, Ted R.
    Weinblatt, Michael
    RHEUMATOLOGY, 2024, 63
12345